InFLAMES Corporate Corner – Immunoprofiling and Immunodrug Development

Brinter attending InFLAMES Corporate Corner – Immunoprofiling and Immunodrug Development

26.1.2023

Brinter, a leading provider of 3D bioprinting technology, recently attended a highly-anticipated Immunoprofiling and Immunodrug Development Seminar and Networking Event held in Turku, Finland. The event brought together some of the brightest minds in the field of immunology and biotechnology, providing a platform for cutting-edge research, discussion, and collaboration.

The seminar showcased the latest developments in immunoprofiling and immunodrug development, with a focus on advanced technologies and innovative approaches. Experts from academia and industry shared their insights on the latest trends and breakthroughs in the field, with a particular emphasis on the potential applications of these technologies in personalized medicine.

Brinter was among the key participants in the event, showcasing their unique 3D bioprinting technology. The company’s Scientist Antti Arjonen was discussing on the use of 3D bioprinting for immunoprofiling and immunodrug development, highlighting the advantages of this technology in the field of personalized medicine.

As a leader in the field of 3D bioprinting, we are committed to advancing the development of personalized medicine through our innovative technology. This event has provided us with a valuable platform to showcase our capabilities and to collaborate with other experts in the field.”

The event was a major success, with attendees from across the globe sharing their expertise and knowledge. The seminar and networking event provided a unique opportunity for professionals in the field to learn about the latest advancements, exchange ideas, and foster new collaborations.

Brinter’s participation in the seminar is part of the company’s ongoing commitment to advancing the field of personalized medicine through the use of 3D bioprinting. The company’s technology has the potential to revolutionize the way in which immunoprofiling and immunodrug development are conducted, opening up new avenues for personalized medicine and precision healthcare.